Analyst Price Targets — NSPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 5, 2026 10:51 am | Adam Maeder | Piper Sandler | $3.00 | $1.17 | TheFly | InspireMD price target lowered to $3 from $4 at Piper Sandler |
| May 4, 2026 12:51 pm | — | Lake Street | $4.00 | $1.18 | TheFly | InspireMD price target lowered to $4 from $5 at Lake Street |
| February 24, 2026 1:55 pm | Frank Takkinen | Loop Capital Markets | $5.00 | $1.82 | StreetInsider | Lake Street Capital Markets Reiterates Buy Rating on InspireMD (NSPR) |
| February 2, 2026 12:44 pm | — | Maxim Group | $6.00 | $1.68 | TheFly | InspireMD initiated with a Buy at Maxim |
| December 11, 2024 1:48 pm | Frank Takkinen | Lake Street | $5.00 | $3.17 | TheFly | InspireMD initiated with a Buy at Lake Street |
| September 17, 2024 7:17 am | Adam Maeder | Piper Sandler | $4.50 | $2.61 | StreetInsider | Piper Sandler Reiterates Overweight Rating on InspireMD (NSPR) |
Latest News for NSPR
NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.
MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to six (6) new non-executive employees in the aggregate amount of 91,161 shares of restricted stock (the “Inducement…
MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial of the CGuard Prime 80cm implant for use in transcarotid artery revascularization (TCAR) procedures. InspireMD anticipates potential approval of the CGuard Prime…
MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), for use with its CGuard Prime 80 cm stent platform, in transcarotid artery…
InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NSPR.
U.S. House Trading
No House trades found for NSPR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.